Spark Therapeutics Presents Updated Preliminary Data from Hemophilia B Phase 1/2 Trial
Spark Therapeutics issued a press release on updated preliminary data from 10 infused participants in the ongoing Phase 1/2 clinical trial of investigational SPK-9001 for hemophilia B. The data is being presented at Hemostastis & Thrombosis Research Society (HTRS) this week.
The press release can be read in full here.
Assisting and Advocating for the Bleeding Disorders Community